致心律失常性右心室心肌病的治疗管理
本文综述致心律失常性右心室心肌病(ARVC)的治疗管理。该病由特定突变导致心室心肌纤维脂肪替代,引发室性心律失常和心源性猝死。抗心律失常药物证据有限,射频消融联合心内外膜消融效果较好,植入式心律转复除颤器可降低心律失常死亡但需权衡并发症风险。
要点
- 抗心律失常药物证据有限,β受体阻滞剂疗效不确切,氟卡尼联合比索洛尔可能有效。
- 射频消融可破坏室速环路,联合心内外膜消融效果更佳,可考虑作为首次手术策略。
- ICD是减少心律失常死亡的关键干预,但需仔细考虑不适当放电和器械并发症风险。
核心结论
- ARVC治疗管理具有挑战性,因进行性纤维化、表型变异和小样本患者队列限制了有意义临床试验的开展。
研究设计与样本
- 本文为综述,检索范围未明确报告。
主要发现
- 抗心律失常药物证据基础有限,β受体阻滞剂理论上合理但降低心律失常风险的疗效不稳健。
- 索他洛尔和胺碘酮的影响不一致,研究报道结果矛盾。
- 新兴证据提示氟卡尼联合比索洛尔可能有效。
- 射频消融在破坏室速环路方面显示一定潜力,联合心内外膜消融效果更好,可考虑在首次手术中采用。
- 立体定向放疗可能成为未来选项,通过改变Nav1.5通道、Connexin 43和Wnt信号水平影响心肌纤维化。
关键数值与推荐
- 未来疗法如腺病毒和GSk3b调节仍处于早期研究阶段。
- ICD植入是减少心律失常死亡的关键干预,但必须仔细考虑不适当放电和器械并发症的风险。
临床怎么用
- 抗心律失常药物选择需权衡有限证据,可考虑氟卡尼联合比索洛尔。
- 射频消融可考虑联合心内外膜消融作为首次手术策略。
- ICD植入应个体化评估获益与不适当放电及并发症风险。
局限性
- 进行性纤维化、表型变异和小样本患者队列限制了开展有意义的临床试验。
- 抗心律失常药物证据基础有限,索他洛尔和胺碘酮研究结果矛盾。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a disease characterised by fibrofatty replacement of the ventricular myocardium due to specific mutations, leading to ventricular arrhythmias and sudden cardiac death. Treating this condition can be challenging due to progressive fibrosis, phenotypic variations and small patient cohorts limiting the feasibility of conducting meaningful clinical trials. Although widely used, the evidence base for anti-arrhythmic drugs is limited. Beta-blockers are theoretically sound, yet their efficacy in reducing arrhythmic risk is not robust. Additionally, the impact of sotalol and amiodarone is inconsistent with studies reporting contradictory results. Emerging evidence suggests that combining flecainide and bisoprolol may be efficacious.Radiofrequency ablation has shown some potential in disrupting ventricular tachycardia circuits, with combined endo and epicardial ablation yielding better results which could be considered at the index procedure. In addition, stereotactic radiotherapy may be a future option that can decrease arrhythmias beyond simple scar formation by altering levels of Nav1.5 channels, Connexin 43 and Wnt signalling, potentially modifying myocardial fibrosis.Future therapies, such as adenoviruses and GSk3b modulation, are still in early-stage research. While implantable cardioverter-defibrillator implantation is a key intervention for reducing arrhythmic death, the risks of inappropriate shocks and device complications must be carefully considered.
引用
- Al-Aidarous S, Protonotarios A, Elliott PM, et al. Management of arrhythmogenic right ventricular cardiomyopathy. Heart. 2024. PMID: 37433658. doi:10.1136/heartjnl-2023-322612
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。